Maze Therapeutics (MAZE) Enterprise Value (2024 - 2026)
Maze Therapeutics (MAZE) posted Enterprise Value of -$352.4 million for Q1 2026, down 3.06% sequentially from -$341.9 million in Q4 2025, and down 19.71% YoY from -$438.9 million in Q1 2025.
Maze Therapeutics (MAZE) Enterprise Value (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Enterprise Value for 3 years, with the latest figure at -$352.4 million in Q1 2026.
- Quarterly Enterprise Value fell 19.71% year-over-year to -$352.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$352.4 million (down 19.71% YoY) and the FY2025 annual result came in at -$341.9 million, down 73.73% from the prior year.
- Enterprise Value slipped to -$352.4 million in Q1 2026 per MAZE's latest filing, from -$341.9 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$30.0 million in Q1 2024 and troughed at -$383.9 million in Q3 2025.
- A 3-year average of -$243.2 million and a median of -$264.5 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value slumped 880.49% in 2025, then slipped 19.71% in 2026.
- Over 3 years, Enterprise Value stood at -$196.8 million in 2024, then plunged by 73.73% to -$341.9 million in 2025, then retreated by 3.06% to -$352.4 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$352.4 million, -$341.9 million, and -$383.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | -411.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -411.09 Mn |
| Mar 31, 2026 | -352.38 Mn |
| Dec 31, 2025 | -341.92 Mn |
| Sep 30, 2025 | -383.94 Mn |
| Jun 30, 2025 | -264.54 Mn |
| Mar 31, 2025 | -294.37 Mn |
| Dec 31, 2024 | -196.81 Mn |
| Sep 30, 2024 | -149.61 Mn |
| Jun 30, 2024 | -175.07 Mn |
| Mar 31, 2024 | -30.02 Mn |